Top Line: Should the extent of lymph node dissection for early-stage lung adenocarcinoma depend less on dogma and more on individual tumor characteristics?
The Study: A large multicenter database analysis examined 27,191 patients undergoing resection for cT1N0M0 lung adenocarcinoma. Specifically it inquired if survival outcomes differed per adherence to lymph node dissection standards, either the “3+1” (minimum of one N1 and three N2) or the more stringent 6-station (one subcarinal plus two additional N2 and three N1). Tumors were stratified into lepidic with no high-grade features versus high-grade or no lepidic pattern. Lepidic tumors had vanishingly low nodal involvement (≤1% for ≤2 cm tumors), in stark contrast to high-grade tumors with a rate of 10–15%. It is no surprise, then, that overall survival for lepidic tumors was excellent (99%) regardless of nodal dissection extent with lepidic tumors, with no survival benefit from guideline adherence. Here we’ll also mention this obviates any potential therapeutic benefit with surgery over ablative radiation due to the former including a formal nodal assessment. On the other hand, high-grade tumors derived a modest but statistically significant survival benefit from guideline-concordant dissection (HR 0.81 for 3+1; HR 0.61 for 6-station), albeit with small absolute gains of 1% at 3 years translating to a number-needed-to-treat of 80–100. Exploratory analyses hinted that tumor size may refine this further with 3+1 sufficing for 1–2 cm, while 6-station may edge ahead in 2–3 cm disease.
TBL: Guideline-concordant nodal sampling appears to matter most for high-grade tumors >2 cm. | Li, JAMA Oncol 2026
The Study: A large multicenter database analysis examined 27,191 patients undergoing resection for cT1N0M0 lung adenocarcinoma. Specifically it inquired if survival outcomes differed per adherence to lymph node dissection standards, either the “3+1” (minimum of one N1 and three N2) or the more stringent 6-station (one subcarinal plus two additional N2 and three N1). Tumors were stratified into lepidic with no high-grade features versus high-grade or no lepidic pattern. Lepidic tumors had vanishingly low nodal involvement (≤1% for ≤2 cm tumors), in stark contrast to high-grade tumors with a rate of 10–15%. It is no surprise, then, that overall survival for lepidic tumors was excellent (99%) regardless of nodal dissection extent with lepidic tumors, with no survival benefit from guideline adherence. Here we’ll also mention this obviates any potential therapeutic benefit with surgery over ablative radiation due to the former including a formal nodal assessment. On the other hand, high-grade tumors derived a modest but statistically significant survival benefit from guideline-concordant dissection (HR 0.81 for 3+1; HR 0.61 for 6-station), albeit with small absolute gains of 1% at 3 years translating to a number-needed-to-treat of 80–100. Exploratory analyses hinted that tumor size may refine this further with 3+1 sufficing for 1–2 cm, while 6-station may edge ahead in 2–3 cm disease.
TBL: Guideline-concordant nodal sampling appears to matter most for high-grade tumors >2 cm. | Li, JAMA Oncol 2026